Appili Therapeutics Financials

APLI Stock  CAD 0.03  0.01  14.29%   
We suggest to use Appili Therapeutics fundamental analysis to find out if markets are presently mispricing the company. Put another way you can use it to find out if Appili Therapeutics is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to break down and interpolate data for thirty available fundamental indicators for Appili Therapeutics, which can be compared to its peers. The stock experiences a very speculative upward sentiment. Check odds of Appili Therapeutics to be traded at C$0.0285 in 90 days. Key indicators impacting Appili Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.140.15
Significantly Down
Slightly volatile
  
Understanding current and past Appili Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Appili Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Appili Therapeutics' assets may result in an increase in income on the income statement.

Appili Therapeutics Stock Summary

Appili Therapeutics competes with Medicenna Therapeutics, and Cardiol Therapeutics. Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada. APPILI THERAPEUTICS is traded on Toronto Stock Exchange in Canada.
Foreign Associate
  Canada
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentCanada Stock View All
ExchangeToronto Exchange
ISINCA03783R1073
Business Address21-1344 Summer Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websiteappilitherapeutics.com
Phone902 442 4655
CurrencyCAD - Canadian Dollar
You should never invest in Appili Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Appili Stock, because this is throwing your money away. Analyzing the key information contained in Appili Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Appili Therapeutics Key Financial Ratios

Appili Therapeutics' financial ratios allow both analysts and investors to convert raw data from Appili Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Appili Therapeutics over time and compare it to other companies across industries.

Appili Therapeutics Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets18.3M8.3M3.1M1.5M1.3M1.3M
Other Current Liab167.6K117.6K229.9K75.8K68.2K64.8K
Net Tangible Assets4.4M8.8M12.8M(3.3M)(3.8M)(3.6M)
Net Debt(10.0M)(1.7M)5.2M8.1M9.3M9.8M
Retained Earnings(31.0M)(56.1M)(65.3M)(69.1M)(62.2M)(59.1M)
Accounts Payable4.5M6.5M2.8M4.1M4.7M3.1M
Cash11.1M6.7M2.5M94.5K85.0K80.8K
Long Term Debt947.3K4.9M7.6M875.2K1.0M956.2K
Net Receivables1.7M1.4M420.8K1.2M1.1M817.8K
Long Term Debt Total950.5K947.3K4.9M7.6M8.7M9.1M
Capital Surpluse1.8M2.6M5.0M6.4M7.4M7.7M
Other Current Assets451.0K183.5K231.1K192.4K221.3K231.3K
Total Liab5.6M11.6M10.5M12.4M14.3M15.0M
Total Current Assets18.3M8.2M3.1M1.5M1.3M1.2M
Short Term Debt85.3K95.6K113.1K7.3M8.4M8.8M
Common Stock21.0M35.0M39.7M42.3M48.7M28.4M
Net Invested Capital13.8M1.7M268.4K(2.7M)(2.5M)(2.3M)
Short Long Term Debt85.3K95.6K113.1K7.3M8.4M8.8M
Net Working Capital13.6M1.6M140.6K(10.1M)(9.1M)(8.6M)
Capital Stock21.0M35.0M39.7M42.3M48.7M35.1M

Appili Therapeutics Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Income117.0K33.7K1.4M16.8K19.3K18.4K
Interest Expense69.8K1.6M1.1M1.6M1.9M2.0M
Gross Profit(14.8K)1.4M327.9K813.7K935.8K982.6K
Operating Income(16.3M)(24.7M)(7.9M)(8.0M)(7.2M)(7.6M)
Ebit(16.3M)(23.5M)(7.7M)(8.0M)(7.2M)(7.6M)
Research Development11.5M21.5M3.8M5.6M6.5M7.8M
Ebitda(16.3M)(23.5M)(7.7M)(8.0M)(7.2M)(7.6M)
Income Before Tax(15.0M)(25.1M)(9.2M)(3.7M)(3.4M)(3.5M)
Net Income(14.3M)(25.1M)(9.2M)(3.8M)(3.4M)(3.6M)
Income Tax Expense(627.9K)38.5K36.4K39.9K45.8K48.1K
Net Interest Income47.1K(1.5M)(1.1M)(1.6M)(1.5M)(1.4M)

Appili Therapeutics Key Cash Accounts

202020212022202320242025 (projected)
Investments(5.0M)5.1M(3.2K)(29.1K)(33.4K)(31.8K)
Change In Cash553.3K(4.4M)(4.2M)(2.4M)(2.1M)(2.0M)
Net Borrowings49.6K189.2K(17.6K)3.8M4.4M4.6M
Free Cash Flow(11.5M)(19.1M)(10.1M)(2.6M)(2.3M)(2.4M)
Depreciation14.8K12.6K6.3K13.7K12.3K11.4K
Other Non Cash Items23.0K1.6M1.1M1.3M1.6M1.6M
Capital Expenditures8.4K2.1K3.2K29.7K26.7K14.8K
Net Income(14.3M)(25.1M)(9.2M)(3.8M)(3.4M)(3.6M)
End Period Cash Flow11.1M6.7M2.5M94.5K85.0K80.8K
Change To Netincome546.1K694.0K1.2M3.5M4.1M4.3M

Appili Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Appili Therapeutics's current stock value. Our valuation model uses many indicators to compare Appili Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Appili Therapeutics competition to find correlations between indicators driving Appili Therapeutics's intrinsic value. More Info.
Appili Therapeutics is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers . At this time, Appili Therapeutics' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Appili Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Appili Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Appili Therapeutics Systematic Risk

Appili Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Appili Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Appili Therapeutics correlated with the market. If Beta is less than 0 Appili Therapeutics generally moves in the opposite direction as compared to the market. If Appili Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Appili Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Appili Therapeutics is generally in the same direction as the market. If Beta > 1 Appili Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.

Appili Therapeutics Total Assets Over Time

Today, most investors in Appili Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Appili Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Appili Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.0172

At this time, Appili Therapeutics' Price Earnings To Growth Ratio is very stable compared to the past year.

Appili Therapeutics March 15, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Appili Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Appili Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Appili Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Appili Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Appili Therapeutics's daily price indicators and compare them against related drivers.

Other Information on Investing in Appili Stock

Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.